ZIOPHARM announces darinaparsin preclinical data on prostate cancer

[News]

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

More... (http://www.news-medical.net/news/20111114/ZIOPHARM-announces-darinaparsin-preclinical-data-on-prostate-cancer.aspx)